PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30691084-0	2019	Evaluation of the Performance of 18F-Fluorothymidine Positron Emission Tomography/Computed Tomography (18F-FLT-PET/CT) in Metastatic Brain Lesions.	18f-fluorothymidine	33-52	fms related receptor tyrosine kinase 1	Homo sapiens	107-110
31119602-7	2019	Results of in vitro and in vivo tumor proliferation experiments and 18F-fluorothymidine (18F-FLT) micro-positron emission tomography/computed tomography (micro-PET/CT) imaging showed that the combined NES1 gene therapy and 131I radiation therapy mediated by overexpressed hNIS protein had the best tumor proliferative inhibition effect.	18f-fluorothymidine	68-87	kallikrein related peptidase 10	Homo sapiens	201-205
29063854-1	2017	PURPOSE: To investigate the associations between interim tumor responses on 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and 18F-fluorothymidine (18F-FLT) PET and patient outcomes, especially progression-free survival (PFS) and overall survival (OS), in non-small cell lung cancer (NSCLC) patients.	18f-fluorothymidine	148-167	fms related receptor tyrosine kinase 1	Homo sapiens	173-176
29398577-14	2018	Baseline angioprotein-1 and hepatocyte growth factor showed a direct correlation with tumor volume whereas changes in vascular cell adhesion molecule 1 showed significant correlations with 18F-fluorothymidine (FLT) positron emission tomography (PET).	18f-fluorothymidine	189-208	vascular cell adhesion molecule 1	Homo sapiens	118-151
30691084-1	2019	18F-fluorothymidine (18F-FLT) is a radiolabeled thymidine analog that has been reported to help monitor tumor proliferation and has been studied in primary brain tumors; however, knowledge about 18F-FLT positron emission tomography/computed tomography (PET/CT) in metastatic brain lesions is limited.	18f-fluorothymidine	0-19	fms related receptor tyrosine kinase 1	Homo sapiens	25-28
30691084-1	2019	18F-fluorothymidine (18F-FLT) is a radiolabeled thymidine analog that has been reported to help monitor tumor proliferation and has been studied in primary brain tumors; however, knowledge about 18F-FLT positron emission tomography/computed tomography (PET/CT) in metastatic brain lesions is limited.	18f-fluorothymidine	0-19	fms related receptor tyrosine kinase 1	Homo sapiens	199-202
29618618-1	2018	Purpose: Our aim was to test whether imaging with 18F-fluorothymidine (18F-FLT) PET/CT was able to detect the combined effects of EGFR and MET inhibitors in oncogene-driven non-small cell lung cancer (NSCLC) and to elucidate the mechanisms underlying the enhanced efficacy of drug combination.Experimental Design: NSCLC cells bearing MET amplification (H1993 and H820) were treated with EGFR and MET inhibitors either alone or in combination and then tested for cell viability and inhibition of signaling.	18f-fluorothymidine	50-69	epidermal growth factor receptor	Mus musculus	130-134
28091565-1	2017	The purpose of this study was to explore the feasibility of 18F-Fluorothymidine (18F-FLT) and 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) in predicting treatment response of nasopharyngeal carcinoma (NPC).	18f-fluorothymidine	60-79	fms related receptor tyrosine kinase 1	Homo sapiens	85-88
25667480-1	2015	AIM: To evaluate the proliferation activity in gliomas using 18F-fluorothymidine (18F-FLT)-positron emission tomography/computed tomography (PET/CT).	18f-fluorothymidine	61-80	fms related receptor tyrosine kinase 1	Homo sapiens	86-89
26973200-5	2016	18F-fluorothymidine (18F-FLT) is a marker of cellular proliferation.	18f-fluorothymidine	0-19	fms related receptor tyrosine kinase 1	Homo sapiens	25-28
32513905-3	2020	Based on increased expression of thymidylate synthase (TYMS), thymidine kinase-1 (TK-1) and SLC29A1 (Equilibrative nucleoside transporter 1, ENT1) in HCC compared with liver tissue, we conducted a proof of concept study evaluating the efficacy of 18F-fluorothymidine (18F-FLT)-PET to assess response to TACE.	18f-fluorothymidine	247-266	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	141-145
24137387-3	2013	18F-fluorothymidine (18F-FLT) positron emission tomography (PET) is used to assess tumor proliferation, since the FLT uptake level reflects thymidine kinase-1 (TK-1) activity.	18f-fluorothymidine	0-19	fms related receptor tyrosine kinase 1	Homo sapiens	25-28
24137387-3	2013	18F-fluorothymidine (18F-FLT) positron emission tomography (PET) is used to assess tumor proliferation, since the FLT uptake level reflects thymidine kinase-1 (TK-1) activity.	18f-fluorothymidine	0-19	fms related receptor tyrosine kinase 1	Homo sapiens	114-117
24137387-3	2013	18F-fluorothymidine (18F-FLT) positron emission tomography (PET) is used to assess tumor proliferation, since the FLT uptake level reflects thymidine kinase-1 (TK-1) activity.	18f-fluorothymidine	0-19	thymidine kinase 1	Homo sapiens	140-158
24137387-3	2013	18F-fluorothymidine (18F-FLT) positron emission tomography (PET) is used to assess tumor proliferation, since the FLT uptake level reflects thymidine kinase-1 (TK-1) activity.	18f-fluorothymidine	0-19	thymidine kinase 1	Homo sapiens	160-164
21667030-0	2011	18F-fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts.	18f-fluorothymidine	0-19	thyroid stimulating hormone receptor	Mus musculus	20-23
21667030-1	2011	We investigated whether 18F-fluorothymidine-positron-emission tomography/computed tomography (18F-FLT-PET/CT) is useful for the evaluation of the very early response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab therapy in human lung cancer xenografts.	18f-fluorothymidine	24-43	thyroid stimulating hormone receptor	Mus musculus	102-105
21667030-1	2011	We investigated whether 18F-fluorothymidine-positron-emission tomography/computed tomography (18F-FLT-PET/CT) is useful for the evaluation of the very early response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab therapy in human lung cancer xenografts.	18f-fluorothymidine	24-43	epidermal growth factor receptor	Homo sapiens	169-206
21667030-1	2011	We investigated whether 18F-fluorothymidine-positron-emission tomography/computed tomography (18F-FLT-PET/CT) is useful for the evaluation of the very early response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab therapy in human lung cancer xenografts.	18f-fluorothymidine	24-43	epidermal growth factor receptor	Homo sapiens	208-212